10-Q: Tharimmune Faces Going Concern Amid Leadership Shift

Tharimmune, a clinical-stage biotech, reported continued operating losses and a going concern warning, despite progress in its drug pipeline and recent capital raises, alongside significant management changes.

Summary

• Tharimmune incurred an operating loss of approximately $4.4 million for the six months ended June 30, 2025, a slight improvement from $4.6 million in the same period of 2024.
• Net cash used in operating activities decreased to $3.8 million for the six months ended June 30, 2025, compared to $5.0 million in the prior year period.
• The company's cash and cash equivalents stood at $2.24 million as of June 30, 2025, down from $3.56 million at December 31, 2024.
• An accumulated deficit of approximately $41.3 million was reported as of June 30, 2025.
• Tharimmune received positive FDA feedback for a 505(b)(2) New Drug Application (NDA) pathway for TH104 for temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders entering an area contaminated with high-potency opioids (PrHPO), which is now the lead program.
• The company plans a capital-efficient strategy for the PrHPO NDA, focusing on Chemistry, Manufacturing, and Controls (CMC) without requiring additional clinical trials for prophylactic dosing.
• Randy Milby resigned as CEO effective June 11, 2025, receiving a $133,500 gross payment and immediate vesting of unvested stock options.
• Sireesh Appajosyula was appointed CEO and Vincent Lopriore was appointed Executive Chairman of the Board, both effective June 11, 2025, with annual base salaries of $285,000 and target bonuses of 60% of base salary.
• The company successfully raised approximately $5.9 million in combined net proceeds from private placement offerings (PIPEs) in June 2024, December 2024, and June 2025.
• Additional capital raises occurred in July 2025, including a registered direct public offering of $1.74 million and a private placement of approximately $1.1 million.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the explicit 'going concern' warning and continued significant cash burn, despite successful capital raises and positive FDA feedback on a key program. The increase in G&A expenses also adds to the financial pressure. While pipeline progress is positive, the fundamental financial stability remains a major concern.

Positives

• Net loss slightly decreased to $4.4 million for the six months ended June 30, 2025, from $4.6 million in the prior year.
• Net cash used in operating activities improved significantly, decreasing to $3.8 million from $5.0 million year-over-year.
• Positive FDA feedback for TH104's PrHPO indication, including a 505(b)(2) NDA pathway and no additional clinical trials for prophylactic dosing, suggests a potentially faster and more capital-efficient path to market.
• Successful completion of multiple capital raises, including $5.9 million from PIPE offerings and an additional $2.84 million in July 2025, provides necessary funding.
• The company is actively progressing its Chemistry, Manufacturing, and Controls (CMC) plan for TH104 to meet FDA NDA requirements.

Negatives

• The company reported an accumulated deficit of approximately $41.3 million as of June 30, 2025, indicating significant historical losses.
• Cash and cash equivalents decreased to $2.24 million as of June 30, 2025, from $3.56 million at the end of 2024, reflecting continued cash burn.
• General and administrative expenses increased by $0.6 million, or 21%, to $3.3 million for the six months ended June 30, 2025, primarily due to higher stock compensation, investor relations, and director remuneration.
• The company has concluded that prevailing conditions and ongoing liquidity risks raise substantial doubt about its ability to continue as a going concern for at least one year.
• Interest income decreased significantly by 90% to $15,604 for the six months ended June 30, 2025, due to lower cash balances.

Risks

• Substantial doubt about the company's ability to continue as a going concern for at least one year due to recurring negative cash flows and limited operating history.
• Need to raise substantial additional capital to fund future operations, with no assurance of obtaining it on acceptable terms or at all.
• Failure to obtain sufficient additional funding could adversely affect business objectives, product development timelines, and may result in delaying or terminating clinical trial activities.
• Uncertainty regarding the success, cost, and timing of clinical trials for product candidates (TH104, TH023, HS1940, HS3215).
• Dependence on third parties for the conduct of clinical trials and manufacturing of drug supplies.
• Ability to obtain necessary regulatory approvals to market and commercialize product candidates is not assured.
• Potential for results of pre-clinical and clinical trials to indicate product candidates are unsafe or ineffective.
• Ability to obtain and maintain intellectual property protection for current and future product candidates.
• Potential for substantial costs from lawsuits to enforce or protect intellectual property rights, or from third-party claims of infringement.
• Reliance on third-party suppliers and manufacturers.
• Success of competing therapies and products that are or become available.
• Ability to expand the organization and retain/attract key personnel.
• Potential for substantial costs resulting from product liability lawsuits.
• Market acceptance of product candidates, and the size and growth of potential markets.
• General business and economic conditions, including inflationary pressures, geopolitical conditions, and trade barriers.

Future Outlook

Tharimmune intends to pursue a capital-efficient strategy to file a New Drug Application (NDA) for TH104 for the temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders entering an area contaminated with high-potency opioids (PrHPO), which is expected to be the lead program. This involves actively progressing its Chemistry, Manufacturing, and Controls (CMC) plan to meet stringent FDA requirements. The company plans to pursue the pruritus in Primary Biliary Cholangitis (PBC) indication for TH104 subsequent to the PrHPO NDA. Additionally, Tharimmune aims to obtain regulatory authorization to initiate a first-in-human bioavailability clinical trial for TH023, advance HS1940 and HS3215 through preclinical and clinical paths, and continue discovery activities for next-generation multi-specific antibodies. The company also seeks strategic collaboration opportunities, including partnering and potential merger and acquisition transactions, to maximize pipeline value.

Management Comments

• We are actively progressing our Chemistry, Manufacturing, and Controls (CMC) plan to meet the stringent requirements for filing an NDA with the FDA for TH104.
• The FDA advised that we will need to perform additional nonclinical studies (i.e., in vitro toxicology studies), but the FDA confirmed that it does not believe any additional clinical trials will be required to define the prophylactic dosing window prior to IND or NDA submission for this indication, which we expect will be the lead program for the Company.

Industry Context

Tharimmune operates in the highly competitive and capital-intensive biotechnology sector, focusing on immunology and inflammation. The shift of TH104's lead indication to PrHPO, leveraging a 505(b)(2) pathway, suggests a strategic move to potentially accelerate market entry and reduce development costs compared to a full de novo clinical program, a common strategy for companies seeking to optimize capital efficiency. The continued reliance on equity financing and the 'going concern' warning are typical challenges for clinical-stage biotechs that have not yet commercialized products and are heavily dependent on R&D success and investor funding. The focus on bispecific antibodies and novel delivery platforms (Soteria and Phloral) aligns with broader industry trends towards more targeted and efficient therapeutic modalities.

Comparison to Industry Standards

• The company's accumulated deficit of over $41 million and recurring negative cash flows are common for clinical-stage biotechnology companies, which typically incur significant R&D expenses without corresponding revenue generation during their development phases. For example, many small-cap biotechs like Athersys, Inc. or Sorrento Therapeutics, Inc. (prior to their financial distress) also reported substantial accumulated deficits and relied heavily on capital raises.
• The decrease in R&D expenses by 44% for the six months ended June 30, 2025, while potentially a positive for cash burn, could also indicate a slowdown in development activities compared to peers, unless it reflects a strategic shift towards more capital-efficient pathways like the 505(b)(2) for TH104.
• The increase in G&A expenses by 21% suggests growing operational overhead, which is a concern for a company with a 'going concern' warning. Efficient G&A management is crucial for small biotechs to extend their cash runway.
• The successful capital raises, totaling approximately $8.74 million in recent months, are critical for survival, but the continuous need for funding and the 'going concern' disclosure highlight a higher financial risk profile compared to more established pharmaceutical companies or biotechs with commercialized products.
• The strategic pivot for TH104 to the PrHPO indication via a 505(b)(2) pathway is a recognized industry approach to de-risk and accelerate drug development by leveraging existing safety and efficacy data of approved drugs, potentially reducing the extensive clinical trial requirements seen in novel drug development (e.g., a 505(b)(1) pathway). This strategy is often employed by companies seeking to optimize their limited capital, similar to how companies might pursue orphan drug designations to streamline development.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings or claims are currently known that would have a material adverse effect on the business, financial condition, or operating results.

Related Party Transactions

• The company's Executive Chairman, Vincent Lopriore, is a partner and licensed broker at President Street Global, a consultant for the company. His combined ownership, individually and through President Street Global, is approximately 17.35% of outstanding common stock.
• During the six months ended June 30, 2025, the Chairman purchased 337,338 common shares in the June 2025 PIPE Offering for $500,000.
• The company made payments of $0.7 million to President Street Global for services rendered during the six months ended June 30, 2025, including offering commissions as the broker in the June 2025 PIPE Offering.
• The CEO, Sireesh Appajosyula, individually and through companies he manages, collectively owns 3.53% of outstanding common stock (including vested options).
• During the six months ended June 30, 2025, the CEO purchased 60,806 common shares in the June 2025 PIPE Offering.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing and future capital raises. The 'going concern' warning indicates high financial risk, potentially impacting share value. However, pipeline progress and strategic shifts offer long-term upside potential if successful.
• **Employees**: Management changes, including a new CEO and Executive Chairman, could lead to shifts in corporate culture or strategy. Compensation plans, including stock options, are in place to incentivize performance.
• **Customers (Future)**: The progress of TH104 towards an NDA for PrHPO could eventually provide a new therapeutic option for military personnel and chemical incident responders.
• **Creditors**: The company's reliance on equity financing and the 'going concern' warning suggest increased risk for creditors, although a promissory note for legal fees is being repaid.
• **Suppliers/Partners**: Continued R&D activities and licensing agreements (Avior, Intract) indicate ongoing engagement, but the company's liquidity challenges could impact future commitments or payment terms.

Next Steps

• Actively progress Chemistry, Manufacturing, and Controls (CMC) plan for TH104 to meet FDA NDA requirements for the PrHPO indication.
• Submit a 505(b)(2) New Drug Application (NDA) for TH104 for the PrHPO indication.
• Pursue the pruritus in Primary Biliary Cholangitis (PBC) indication for TH104 subsequent to the PrHPO NDA.
• Obtain regulatory authorization to initiate a first-in-human bioavailability clinical trial for TH023.
• Optimize the CMC program for TH023.
• Create a preclinical and clinical path forward for HS1940.
• Continue to advance pre-clinical candidate selection activities against HER2/HER3 receptors with various antibody formats, including HS3215.
• Hasten the discovery of next-generation multi-specific (biand tri) antibodies.
• Pursue strategic collaboration opportunities, including partnering and potential merger and acquisition transactions.
• Seek additional funding through equity or debt securities, strategic partnerships, grants, or other arrangements.

Key Dates

Recommendation

While the company faces a significant 'going concern' risk and has a history of operating losses, recent successful capital raises provide a temporary lifeline. The positive FDA feedback for TH104's PrHPO indication, particularly the 505(b)(2) pathway, offers a more capital-efficient and potentially faster route to market for a lead program. However, the increased general and administrative expenses are a concern. Given the high-risk, high-reward nature of clinical-stage biotech, coupled with the explicit going concern warning, a 'hold' recommendation is appropriate for investors who are already exposed or considering a speculative position. It acknowledges the inherent risks while recognizing the potential upside from pipeline progress and recent funding, but advises against new significant investment until financial stability and clinical milestones are more firmly established.

Keywords

Biotechnology, Clinical-stage, Immunology, Inflammation, TH104, Pruritus, Primary Biliary Cholangitis (PBC), Opioid Overdose Prophylaxis, TH023, Infliximab, TNF-alpha, Immuno-oncology, HER2, HER3, PD-1, HS1940, HS3215, SEC Filing, 10-Q, Going Concern, Capital Raise, Drug Development, FDA Approval